ReviewJACS Au2025
Activatable Porphyrin-Based Sensors, Photosensitizers and Combination Therapeutics.
Review in JACS Au, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Assessment of Double-Hybrid Functionals for the Vertical Excitation Energies of Porphyrins.Molecules (Basel, Switzerland) · 2026Article
- Sustainable Synthesis of 4,7-Dihydro-4,7-ethano-2H-isoindoles-Key Building Blocks to Benzoporphyrins.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- NADH-Triggered Photogenerated Carbon Radicals as General Abstracting Agents for Synergism of Apoptosis and Ferroptosis.JACS Au · 2026Article
- A Multireference Picture of Electronic Excited States in Vanadyl and Copper Tetraphenyl Porphyrin Molecular Qubits.The journal of physical chemistry. A · 2025Article
- Photodynamic therapeutic activity of novel porphyrins against lung squamous cell carcinoma.BMC cancer · 2025Article
- Construction of Triphenylamine-Based Aggregation-Induced Emission Luminogens for Lysosomes Imaging and Its Application in the Photodynamic Therapy of Cancer Cells.Molecules (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porphyrins, known as the "pigments of life", have evolved from their natural roles into versatile tools for biomedical applications. The development of activatable porphyrins has significantly expanded their utility, enabling precise responses to a carefully selected target analyte. These advances have broadened their use in imaging, diagnosis, and therapy. These capabilities are driven by activity-based sensing (ABS), which enhances the selectivity and sensitivity to various disease biomarkers. However, their design and implementation are intrinsically complex. This perspective provides an easy-to-follow roadmap that details how such molecules can be developed. Furthermore, we highlight recent progress in ABS-modified porphyrins, focusing on how specific modifications achieve these remarkable properties across various biomedical platforms. The ongoing evolution of activatable porphyrins holds great promise for the development of sophisticated, responsive systems, offering more effective diagnostic and therapeutic tools.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.